drugset / Trial / NCT00003398
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 4
Completed
45 enrolled
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center · collab
Treatment
Summary
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.
Timeline
- Start
- 1998-09
- Primary completion
- 2000-05
- Completion
- 2000-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Thiotepa | Other / unclassified | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |